Literature DB >> 16645425

Prevalence and causes of persistent use of hormone replacement therapy among postmenopausal women: a follow-up study.

Jose Ness1, Wilbert S Aronow.   

Abstract

In a previous study analyzing data from September 2002 to February 2003, we showed that, despite the Women's Health Initiative trial results, many women still remained on hormone replacement therapy (HRT) in an internal medicine practice. However, it is not known whether such use has persisted over time. We performed a retrospective chart analysis of 1000 postmenopausal women seen at the same internal medicine practice from January 2004 to May 2004 to establish whether the prevalence of HRT use had declined, remained stable, or increased when compared with our previous data and to determine the reasons for continued HRT use. Among 1000 postmenopausal women, mean age 66+/-9 years, 116 (12%) remained on HRT (HRT users) in 2004. The prevalence of HRT users declined from 16% to 12% (P<0.01) over a period of 15 months. Among HRT users, the main reasons for continued use were severe menopausal symptoms in 39 (34%), patient preference in 17 (15%), osteoporosis or osteopenia in 14 (12%), failed attempt at discontinuation in 13 (11%), taper in progress in 12 (10%), gynecologist recommendation in 10 (9%), not documented in 8 (7%), and other reasons in 3 (3%). The use of HRT declined over time in an internal medicine clinic since the publication of the Women's Health Initiative study. However, 12% of the women still remained on HRT in 2004. The severity of menopausal symptoms, patient preference, and osteoporosis or osteopenia played a prominent role in the decision to remain on HRT.

Entities:  

Mesh:

Year:  2006        PMID: 16645425     DOI: 10.1097/00045391-200603000-00004

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  7 in total

1.  Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results.

Authors:  Sybil L Crawford; Carolyn J Crandall; Carol A Derby; Samar R El Khoudary; L Elaine Waetjen; Mary Fischer; Hadine Joffe
Journal:  Menopause       Date:  2018-12-21       Impact factor: 2.953

2.  Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension.

Authors:  Erin J Aiello Bowles; Melissa L Anderson; Susan D Reed; Katherine M Newton; E Dawn Fitzgibbons; Deborah Seger; Diana S M Buist
Journal:  J Womens Health (Larchmt)       Date:  2010-08       Impact factor: 2.681

3.  Hormone therapy use in women veterans accessing veterans health administration care: a national cross-sectional study.

Authors:  Megan R Gerber; Matthew W King; Suzanne L Pineles; Shannon Wiltsey-Stirman; Bevanne Bean-Mayberry; Sandra J Japuntich; Sally G Haskell
Journal:  J Gen Intern Med       Date:  2014-11-06       Impact factor: 5.128

4.  Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial.

Authors:  Sarah E Tom; Melissa L Anderson; Carol A Landis; Erin J Aiello Bowles; Nancy F Woods; Susan D Reed; Katherine M Newton; Diana S M Buist
Journal:  Menopause       Date:  2011-11       Impact factor: 2.953

5.  Short-term (1-2 mo) hormone therapy cessation before mammography.

Authors:  Susan D Reed; Diana S M Buist; Melissa L Anderson; Erin J Aiello Bowles; Dawn Fitzgibbons; Deborah Seger; Katherine M Newton
Journal:  Menopause       Date:  2009 Nov-Dec       Impact factor: 2.953

6.  Epidemiology of ovarian cancer: a review.

Authors:  Brett M Reid; Jennifer B Permuth; Thomas A Sellers
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

7.  Hormonal therapies and venous thrombosis: Considerations for prevention and management.

Authors:  Corinne LaVasseur; Suvi Neukam; Thomas Kartika; Bethany Samuelson Bannow; Joseph Shatzel; Thomas G DeLoughery
Journal:  Res Pract Thromb Haemost       Date:  2022-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.